Atelocollagen sponge and recombinant basic fibroblast growth factor combination therapy for resistant wounds with deep cavities.
Recent advances in bioengineering have introduced materials that enhance wound healing. Even with such new tools, some deep ulcers surrounded by avascular tissues, including bone, tendon, and fascia, are resistant to various therapies and easily form deep cavities with loss of subcutaneous tissue. Atelocollagen sponges have been used as an artificial dermis to cover full-thickness skin defects. Topical recombinant human basic fibroblast growth factor has been introduced as a growth factor to induce fibroblast proliferation in skin ulcers. We applied these materials in combination in two patients with deep resistant wounds: one with a cavity reaching the mediastinum through a divided sternum and one with deep necrotic wounds caused by electric burns. These wounds did not respond to the topical basic fibroblast growth factor alone. In contrast, the combination therapy closed the wounds rapidly without further surgical treatment. This combination therapy is a potent treatment for resistant wounds with deep cavities.
Nakanishi
Asako
A
Department of Dermatology, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
Hakamada
Arata
A
Isoda
Ken-ichi
K
Mizutani
Hitoshi
H
D000368:Aged; D002908:Chronic Disease; D003094:Collagen / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006225:Hand; D006801:Humans; D008875:Middle Aged; D018570:Risk Assessment; D012720:Severity of Illness Index; D012883:Skin Ulcer / Q000175:diagnosis* / Q000628:therapy*; D013249:Sternum; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014945:Wound Healing / Q000502:physiology
C059821:atelocollagen; D016222:Fibroblast Growth Factor 2; D003094:Collagen